For Investors & Partners

Following from founder, institutional and grant funding we are seeking to grow through investment leading to Series A; finding partners with complementary skills and resources; sub-licensing our technology; or acquisition into a larger programme to accelerate impact.

We offer:

  • A proven track record of senior scientific, technology and commercial development expertise.

  • A non-exclusive commercial licence to European Union Tissues and Cells Directive compliant human pluripotent stem cell lines for:

    • treatment of immune dysregulation & extracorporeal applications.

    • Sales and service of derivative products.

  • New intellectual property for a method to prime epithelial to mesenchymal and mesenchymal to epithelial transitions.

  • New intelletual property contained in unpublished cell RNAseq and secreted protein proteomic datasets.

  • Research grade working banks of 2 human pluripotent stem cell lines and differentiated primal cells.

  • Patent for method of differentiation in the UK, Canada and USA expiring March 2026.

Learn more